TW307769B - - Google Patents

Download PDF

Info

Publication number
TW307769B
TW307769B TW082105942A TW82105942A TW307769B TW 307769 B TW307769 B TW 307769B TW 082105942 A TW082105942 A TW 082105942A TW 82105942 A TW82105942 A TW 82105942A TW 307769 B TW307769 B TW 307769B
Authority
TW
Taiwan
Prior art keywords
hydrochloride
patent application
water
crystalline hydrate
hydrate
Prior art date
Application number
TW082105942A
Other languages
English (en)
Chinese (zh)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of TW307769B publication Critical patent/TW307769B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082105942A 1992-07-31 1993-07-26 TW307769B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
TW307769B true TW307769B (enExample) 1997-06-11

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105942A TW307769B (enExample) 1992-07-31 1993-07-26

Country Status (23)

Country Link
US (1) US5407929A (enExample)
EP (1) EP0581552B1 (enExample)
KR (1) KR100245938B1 (enExample)
CN (1) CN1037683C (enExample)
AT (1) ATE165360T1 (enExample)
AU (1) AU657866B2 (enExample)
BR (1) BR9303235A (enExample)
CA (1) CA2101502A1 (enExample)
DE (1) DE69318077T2 (enExample)
ES (1) ES2115725T3 (enExample)
FI (1) FI933391L (enExample)
GR (1) GR3026699T3 (enExample)
HU (1) HU219637B (enExample)
IL (1) IL106516A (enExample)
MX (1) MX9304611A (enExample)
NO (1) NO303734B1 (enExample)
NZ (1) NZ248285A (enExample)
PH (1) PH30109A (enExample)
PL (2) PL172830B1 (enExample)
RU (1) RU2118959C1 (enExample)
TW (1) TW307769B (enExample)
UA (1) UA37181C2 (enExample)
ZA (1) ZA935529B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1757606T3 (da) * 2001-02-24 2009-09-07 Boehringer Ingelheim Pharma Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CA2513837A1 (en) 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Crystalline forms of pitavastatin calcium
CN1751051B (zh) 2003-03-27 2010-06-09 巴斯利尔药物股份公司 结晶形式的头孢菌素
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP5323684B2 (ja) * 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
KR940005636A (ko) 1994-03-22
DE69318077D1 (de) 1998-05-28
FI933391A7 (fi) 1994-02-01
AU657866B2 (en) 1995-03-23
CN1037683C (zh) 1998-03-11
PH30109A (en) 1996-12-27
IL106516A0 (en) 1993-11-15
HU9302194D0 (en) 1993-10-28
NO303734B1 (no) 1998-08-24
ZA935529B (en) 1994-02-24
HU219637B (hu) 2001-06-28
ATE165360T1 (de) 1998-05-15
NZ248285A (en) 1994-07-26
KR100245938B1 (ko) 2000-04-01
AU4422793A (en) 1994-02-03
CN1089948A (zh) 1994-07-27
EP0581552B1 (en) 1998-04-22
HUT68602A (en) 1995-06-28
NO932745L (no) 1994-02-01
RU2118959C1 (ru) 1998-09-20
FI933391A0 (fi) 1993-07-29
IL106516A (en) 1998-06-15
BR9303235A (pt) 1994-03-01
PL299870A1 (en) 1994-02-07
EP0581552A2 (en) 1994-02-02
GR3026699T3 (en) 1998-07-31
PL172835B1 (pl) 1997-12-31
ES2115725T3 (es) 1998-07-01
FI933391L (fi) 1994-02-01
NO932745D0 (no) 1993-07-30
DE69318077T2 (de) 1998-10-29
EP0581552A3 (en) 1994-06-01
US5407929A (en) 1995-04-18
CA2101502A1 (en) 1994-02-01
UA37181C2 (uk) 2001-05-15
MX9304611A (es) 1994-02-28
PL172830B1 (pl) 1997-12-31

Similar Documents

Publication Publication Date Title
TW307769B (enExample)
SA97180739B1 (ar) الشكل البللوري للمتشاكل S - enantiomer للأومبرازول omeprazole
JPH0255437B2 (enExample)
NL192266C (nl) Werkwijze voor het bereiden van een kristallijn cefepime-dihydrochloride alsmede het kristallijne dihydrochloride en mengsels die het bevatten.
JP2009143957A (ja) アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
ES2390611T3 (es) Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico
TWI293631B (enExample)
DK163514B (da) Fremgangsmaade til fremstilling af en krystallinsk form af natriumsaltet af et oximderivat af 7-aminothiazolylacetamidocephalosporansyre
FR2466469A1 (fr) Bischlorhydrate de cephalosporine, son procede de preparation et ses applications, notamment en therapeutique
JPS62294615A (ja) 抗菌剤
KR100332280B1 (ko) 항헬리코박터 필로리제
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
JPH0741484A (ja) セフェム化合物及び抗菌剤
US10717729B2 (en) Thiamine-organic acid salt
CA2082472A1 (en) Crystalline form of a cephalosporin antibiotic
FR2884822A1 (fr) Derives de triazines, leur preparation et leur application en therapeutique
HU204271B (en) Process for producing cristalline 1-carba-dethia-cepheme-solvates
SU973024A3 (ru) Способ получени аддитивных солей пивалоилоксиметилового эфира 7 @ -[2-(2-аминотиазол-4-ил) ацетамидо]-3-[1-(2-диметиламиноэтил)-1н-тетразол-5-илтиометил]-3-цефем-4-карбоновой кислоты с сол ной,винной или лимонной кислотой
FR2952M (enExample)
RU2785195C1 (ru) Способ получения полиморфной формы 4-(3-этокси-4-гидроксибензил)-N-(2,4-дифторфенил)-5-оксо-5,6-дигидро-4H-1,3,4-тиадиазин-2-карбоксамида
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
JPH04234880A (ja) β−ラクタム抗生物質の結晶性塩酸塩
US3835165A (en) Nitrofuryl-alpha-halo-hydrazones
DE69312322T2 (de) Cephem verbindungen mit antimicrobizide eigenschaften
JPS58154589A (ja) セフアロスポリン誘導体